英國研究人員日前報告說,，他們發(fā)現(xiàn)人體尿液中一種蛋白質(zhì)可作為前列腺癌風險標記物,。研究人員認為,，這一發(fā)現(xiàn)有助開發(fā)一種新的,、較為方便的檢測前列腺癌變的技術(shù),。
英國癌癥研究會等機構(gòu)的研究人員在美國學術(shù)期刊《科學公共圖書館綜合卷》上報告說,，這種名為MSMB的蛋白質(zhì)由正常的前列腺細胞產(chǎn)生，其功能是調(diào)控前列腺細胞的死亡,。研究人員對350名男性進行了前列腺組織和尿液取樣,，并檢測他們尿液中MSMB蛋白質(zhì)含量。結(jié)果發(fā)現(xiàn),，與健康男性相比,，患有前列腺癌的男性尿液中MSMB蛋白質(zhì)含量明顯要低。
領(lǐng)導這項研究的海利·惠特克博士說,，檢測尿液中這種蛋白質(zhì)含量的方法非常簡單,，所以它有可能發(fā)展成一種新的、較為方便的檢測前列腺癌的技術(shù),。
目前常規(guī)的前列腺癌檢查方法是基于一種叫做前列腺特異抗原的生物標記物,。但是人體血液中前列腺特異抗原的含量受多種因素影響，從而影響該方法的準確性,。
參與研究的羅莎琳德·伊爾斯表示,，截至目前，檢測血液中前列腺特異抗原含量仍是診斷前列腺癌最有效的方法,，但這種方法有許多局限性,。因此，當務(wù)之急是尋找諸如MSMB蛋白質(zhì)這樣新的生物標記物,，并將其應(yīng)用于前列腺癌的檢查和診斷,。（生物谷Bioon.com）
生物谷推薦英文摘要：
PLoS ONE 5(10): e13363. doi:10.1371/journal.pone.0013363
The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine
Hayley C. Whitaker1*, Zsofia Kote-Jarai2,3#, Helen Ross-Adams1#, Anne Y. Warren4, Johanna Burge1, Anne George1, Elizabeth Bancroft2,3, Sameer Jhavar2,3, Daniel Leongamornlert2,3, Malgorzata Tymrakiewicz2,3, Edward Saunders2,3, Elizabeth Page2,3, Anita Mitra2,3, Gillian Mitchell5, Geoffrey J. Lindeman6, D. Gareth Evans7, Ignacio Blanco8, Catherine Mercer9, Wendy S. Rubinstein10, Virginia Clowes11, Fiona Douglas12, Shirley Hodgson13, Lisa Walker14, Alan Donaldson15, Louise Izatt16, Huw Dorkins17, Alison Male18, Kathy Tucker19, Alan Stapleton20, Jimmy Lam20, Judy Kirk21, Hans Lilja22, Douglas Easton23, The IMPACT Study Steering Committee?a, The IMPACT Study Collaborators?b, UK GPCS Collaborators?c, Colin Cooper2,3, Rosalind Eeles2,3, David E. Neal1
Background
Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk.
Methodology/Principal Findings
MSMB expression in benign and malignant prostate tissue was examined using immunohistochemistry and compared with the rs10993994 genotype. Urinary MSMB concentrations were determined by ELISA and correlated with urinary PSA, the presence or absence of cancer, rs10993994 genotype and age of onset. MSMB levels in prostate tissue and urine were greatly reduced with tumourigenesis. Urinary MSMB was better than urinary PSA at differentiating men with prostate cancer at all Gleason grades. The high risk allele was associated with heterogeneity of MSMB staining and loss of MSMB in both tissue and urine in benign prostate.
Conclusions
These data show that some high risk alleles discovered using genome-wide association studies produce phenotypic effects with potential clinical utility. We provide the first link between a low penetrance polymorphism for prostate cancer and a potential test in human tissue and bodily fluids. There is potential to develop tissue and urinary MSMB for a biomarker of prostate cancer risk, diagnosis and disease monitoring.
